The aim of this study is to investigate the effect of mud compress (MC) therapy compared to hot pack (HP) therapy on cartilage destruction and subchondral bone alterations detected by urine levels of C telopeptide fragment of collagen type-II (uCTX-II) in patients with knee osteoarthritis (OA).
METHODS:
Fifty-nine patients between 49-74 years of age with bilateral knee OA divided into 2 groups. Twenty-five patients (16 females, 9 males) and 34 patients(22 females, 13 males) were given HP versus local natural organic and mineral-rich MC therapy respectively for 2 weeks as a total of 12 sessions. uCTX-II, Visual Analog Scale (VAS), 15 m walking time, Western Ontario and McMaster Universities multifunctional (WOMAC) index were measured at baseline, after-treatment and 3 months after treatment.
RESULTS:
uCTX-II level did not show any difference between the two groups, however it decreased significantly in MC and HP groups 3 months after treatment (p< 0.017). WOMAC stiffness sore was significantly lower in MC group 3 months after treatment (p< 0.05). Both MC and HP therapies lowered VAS, WOMAC total and subscores significantly up to 3 months (p< 0.017).
CONCLUSIONS:
HP and MC therapies for OA of knee are not superior to one another with respect to the level of uCTX-II. MC may probably decrease the ongoing cartilage destruction and related subchonral bone interactions earlier compared to HP treatment in patients with knee OA as evidenced by decreased uCTX-II levels after-treatment.
FelsonDT, LawrenceRC, DieppePA, HirschR, HelmickCG, JordanJM, et al. Osteoarthritis: New insights. Part 1: the disease and its risk factors. Ann Intern Med. 2000; 133(8): 635-46.
2.
National Center for Chronic Disease Prevention and Health Promotion (2014) available at: http://www.cdc.gov/arthritis/basics/osteoarthritis.htm (last visited 26th March 2014).
3.
GarneroP, PipernoM, GineytsE, ChristgauS, DelmasPD, VignonE. Cross sectional evaluation of biochemical markers of bone, cartilage, and synovial tissue metabolism in patientswith knee osteoarthritis: Relations with disease activity and joint damage. Ann Rheum Dis. 2001; 60(6): 619-26.
4.
ChristgauS, GarneroP, FledeliusC, MonizC, EnsigM, GineytsE, et al. Collagen type II C-telopeptide fragments as an index of cartilage degradation. Bone. 2001; 29(3): 209-15.
5.
HollanderAP, HeathfieldTF, WebberC, IwataY, BourneR, RorabeckC, et al. Increased damage to type II collagen in osteoarthritic articular cartilage detected by a new immunoassay. J Clin Invest. 1994; 93(4): 1722-32.
6.
DownsJT, LaneCL, NestorNB, McLellanTJ, KellyMA, KaramGA, et al. Analysis of collagenase-cleavage of type II collagen using a neoepitope ELISA. J Immunol Methods. 2001; 247(1-2): 25-34.
7.
GarneroP, AyralX, RousseauJC, ChristgauS, SandellLJ, DougadosM, et al. Uncoupling of type II collagen synthesis and degradation predicts progression of joint damage in patients withknee osteoarthritis. Arthritis Rheum. 2002; 46(10): 2613-24.
8.
GarneroP, GineytsE, ChristgauS, FinckB, DelmasPD. Association of baseline levels of urinary glucosyl-galactosyl-pyridinoline and type II collagen C-telopeptide with progression of joint destruction in patients with early rheumatoid arthritis. Arthritis Rheum. 2002; 46: 21-30.
9.
ConrozierT, JousseaumeCA, MathieuP, TronAM, CatonJ, BejuiJ, et al. Quantitative measurement of joint space narrowing progression in hip osteoarthritis: A longitudinal retrospective study of patients treated by total hip arthroplasty. Rheumatol. 1998; 37(9): 961-8.
10.
GarneroP, ConrozierT, ChristgauS, MathieuP, DelmasPD, VignonE. Urinary type II collagen C-telopeptide levels are increased in patients with rapidly destructive hip osteoarthritis. Ann Rheum Dis. 2003; 62(10): 939-43.
11.
GarneroP, MazièresB, GuéguenA, AbbalM, BerdahL, LequesneM, et al.J Cross-sectional association of 10 molecular markers of bone, cartilage, and synovium with disease activity andradiological joint damage in patients with hip osteoarthritis: The ECHODIAH cohort. Rheumatol. 2005; 32(4): 697-703.
12.
MeulenbeltI, KloppenburgM, KroonHM, Houwing-DuistermaatJJ, GarneroP, Hellio Le GraverandMP, et al. Urinary CTX-II levels are associated with radiographic subtypes of osteoarthritis in hip, knee, hand, and facet joints in subject with familial osteoarthritis at multiple sites: The GARP study. Ann Rheum Dis. 2006; 65(3): 360-5.
13.
ReijmanM, HazesJM, Bierma-ZeinstraSM, KoesBW, ChristgauS, ChristiansenC, et al. A new marker for osteoarthritis: Cross-sectional and longitudinal approach. Arthritis Rheum. 2004; 50(8): 2471-8.
14.
SowersMF, Karvonen-GutierrezCA, YosefM, JannauschM, JiangY, GarneroP, et al. Longitudinal changes of serum COMP and urinary CTX-II predict X ray defined knee osteoarthritis severity andstiffness in women. Osteoarthritis Cartilage. 2009; 17(12): 1609-14. doi: 10.1016/j.joca.2009.06.001.
15.
BruyereO, ColletteJ, KothariM, ZaimS, WhiteD, GenantH, et al. Osteoarthritis, magnetic resonance imaging, and biochemical markers: a one year prospective study. Ann Rheum Dis. 2006; 65(8): 1050-4.
16.
DamEB, ByrjalsenI, KarsdalMA, QvistP, ChristiansenC. Increased urinary excretion of C-telopeptides of type II collagen (CTX-II) predicts cartilage loss over 21 months byMRI. Osteoarthritis Cartilage. 2009; 17(3): 384-9. doi: 10.1016/j.joca.2008.07.009.
17.
FelsonDT, McLaughlinS, GogginsJ, LaValleyMP, GaleME, TottermanS, et al. Bone marrow edema and its relation to progression of knee osteoarthritis. Ann Intern Med. 2003; 139(5 Pt 1): 330-6.
18.
HunterDJ, ZhangY, NiuJ, GogginsJ, AminS, LaValleyMP, et al. Increase in bone marrow lesions associated with cartilage loss: a longitudinal magnetic resonance imaging studyof knee osteoarthritis. Arthritis Rheum. 2006; 54(5): 1529-35.
19.
BetticaP, ClineG, HartDJ, MeyerJ, SpectorTD. Evidence for increased bone resorption in patients with progressive knee osteoarthritis: longitudinal results from the Chingford study. Arthritis Rheum. 2002; 46(12): 3178-84.
20.
Bay-JensenAC, AndersenTL, Charni-Ben TabassiN, KristensenPW, Kjaersgaard-AndersenP, SandellL, et al. Biochemical markers of type II collagen breakdown and synthesis are positioned at specific sites in humanosteoarthritic knee cartilage. Osteoarthritis Cartilage. 2008; 16(5): 615-23.
21.
Van SpilWE, JansenNW, BijlsmaJW, ReijmanM, DeGrootJ, WelsingPM, et al. Clusters within a wide spectrum of biochemical markers for osteoarthritis: Data from CHECK, a large cohort ofindividuals with very early symptomatic osteoarthritis. Osteoarthritis Cartilage. 2012; 20(7): 745-54. doi: 10.1016/j.joca.2012.04.004.
22.
Societe' Internacionale d'Hydrologie Me' dicale. Decisions prises au cours de la Session 1949. In: Proceedings of the IV e Confe' rence Scientifique Internationale de Dax; 1949 Oct 13-16; Dax, France. Imp. Larrat, p. 156-7.
23.
OdabasiE, KaragulleMZ, KaragulleM, et al. Comparison of two traditional spa therapy regimens in patients with knee osteoarthritis. Phys Med Rehab Kur Med. 2002; 12: 337-341.
24.
WiglerI, ElkayamO, ParanD, YaronM. Spa therapy for gonarthrosis: a prospective study. Rheumatol Int. 1995; 15(2): 65-8.
25.
FlusserD, Abu-ShakraM, FrigerM, CodishS, SukenikS. Therapy with mud compresses for knee osteoarthritis: Comparison of natural mud preparations with mineral-depleted mud. J Clin Rheumatol. 2002; 8(4): 197-203.
26.
ElkayamO, WiglerI, TishlerM, RosenblumI, CaspiD, SegalR, et al. Effect of spa therapy in Tiberias on patients with rheumatoid arthritis and osteoarthritis. J Rheumatol. 1991; 18(12): 1799-803.
CodishS, Abu-ShakraM, FlusserD, FrigerM, SukenikS. Mud compress therapy for the hands of patients with rheumatoid arthritis. Rheumatol Int. 2005; 25(1): 49-54.
29.
ElkayamO, OphirJ, BrenerS, ParanD, WiglerI, EfronD, et al. Immediate and delayed effects of treatment at the Dead Sea in patients with psoriatic arthritis. Rheumatol Int. 2000; 19(3): 77-82.
30.
KaragülleMZ, KaragülleM. Balneotherapy and spa therapy of rheumatic diseases in Turkey: A systematic review. Forsch Komplementarmed Klass Naturheilkd. 2004; 11(1): 33-41.
31.
FioravantiA, PerpignanoG, TirriG, CardinaleG, GiannitiC, LanzaCE, et al. Effects of mud-bath treatment on fibromyalgia patients: a randomized clinical trial. Rheumatol Int. 2007; 27(12): 1157-61.
32.
ArdiçF, OzgenM, AybekH, RotaS, CubukçuD, GökgözA. Effects of balneotherapy on serum IL-1, PGE2 and LTB4 levels in fibromyalgia patients. Rheumatol Int. 2007; 27(5): 441-6.
33.
BasiliS, MartiniF, FerroniP, GrassiM, Sili ScavalliA, StrevaP, et al. Effects of mud pack treatment on plasma cytokine and soluble adhesion molecule levels in healthy volunteer. Clin Chim Acta. 2001; 314(1-2): 209-14.
34.
GüngenG, ArdicF, FındıkoğluG, RotaS. The effect of mud pack therapy on serum YKL-40 and hsCRP levels in patients with knee osteoarthritis. Rheumatol Int. 2012; 32(5): 1235-44. doi: 10.1007/s00296-010-1727-4.
35.
TüzünEH, EkerL, AytarA, DaşkapanA, BayramoğluM. Acceptability, reliability, validity and responsiveness of the Turkish version of WOMAC osteoarthritis index. Osteoarthritis Cartilage. 2005; 13(1): 28-3.
36.
GarneroP, LandewéR, BoersM, VerhoevenA, Van Der LindenS, ChristgaS, et al. Association of baseline levels of markers of bone and cartilage degradation with long-term progression of jointdamage in patients with early rheumatoid arthritis: The COBRA study. Arthritis Rheum. 2002; 46(11): 2847-56.
37.
GarneroP, CharniN, JuilletF, ConrozierT, VignonE. Increased urinary type II collagen helical and C telopeptide levels are independently associated with a rapidlydestructive hip osteoarthritis. Ann Rheum Dis. 2006; 65(12): 1639-44.
38.
GineytsE, MoJA, KoA, HenriksenDB, CurtisSP, GertzBJ, et al. Effects of ibuprofen on molecular markers of cartilage and synovium turnover in patients with knee osteoarthritis. Ann. Rheum Dis. 2004; 63(7): 857-61.
39.
HayamiT, PickarskiM, WesolowskiGA, McLaneJ, BoneA, DestefanoJ, et al. The role of subchondral bone remodeling in osteoarthritis: reduction of cartilage degeneration and revention ofosteophyte formation by alendronate in the rat anterior cruciate ligament transection model. Arthritis Rheum. 2004; 50(4): 1193-206.
40.
AlexandersenP, KarsdalMA, QvistP, ReginsterJY, ChristiansenC. Strontium ranelate reduces the urinary level of cartilage degradation biomarker CTX-II in postmenopausal women. Bone. 2007; 40(1): 218-22.
41.
IwamotoJ, TakedaT, SatoY, MatsumotoH. Effects of risedronate on osteoarthritis of the knee. Yonsei Med J. 2010; 51(2): 164-70. doi: 10.3349/ymj.2010.51.2.164.
42.
OdabasiE, TuranM, ErdemH, TekbasF. Does mud pack treatment have any chemical effect? A randomized controlled clinical study. J Altern Complement Med. 2008; 14(5): 559-65. doi: 10.1089/acm.2008.0003.
TolomioC, Ceschi-BerriniC, MoschinE, GalzignaL. Colonization by diatoms and antirheumatic activity of thermal mud. Cell Biochem Funct. 1999; 17(1): 29-33.
45.
BeerAM, JungingerHE, LukanovJ, SagorchevP. Evaluation of the permeation of peat substances through human skin in vitro. Int J Pharm. 2003; 253(1-2): 169-75.
46.
SagorchevP, BeerA-M, LukanovJ. Influence of aqueous extracts with a definite molecular weight on the spontaneous contractile activity of guinea pig's stomach smooth muscles. Fol. Med. 1999; 42: 37-42.
47.
BeerAM, LukanovJ, SagorchevP. The influence of fulvic and ulmic acids from peat, on the spontaneous contractile activity of smooth muscles. Phytomedicine. 2000; 7(5): 407-15.
48.
BeerAM, SagorchevP, LukanovJ. Isolation of biologically active fractions from the water soluble components of fulvic and ulmic acids from peat. Phytomedicine. 2002; 9(7): 659-66.
49.
CechettinM, BellomettiS, LalliA, GalzignaL. Serum interleukin-1 changes in arthrosis patients after mud-pack treatment. Phys Rehab Kur Med. 1995; 5: 92-93.
BellomettiS, GalzignaL. Serum levels of a prostaglandin and a leukotriene after thermal mud pack therapy. J Investig Med. 1998; 46(4): 140-5.
52.
BellomettiS, RichelmiP, TassoniT, BerteF. Production of matrix metalloproteinases and their inhibitors in osteoarthritic patients undergoing mud bath therapy. Int J Clin Pharmacol Res. 2005; 25(2): 77-94.
53.
BellomettiS, CecchettinM, GalzignaL. Mud pack therapy in osteoarthrosis Changes in serum levels of chondrocyte markers. Clinica Chimica Acta. 1997; 268: 101-106.
54.
BellomettiS, PolettoM, GregottiC, RichelmiP, BertèF. Mud bath therapy influences nitric oxide, myeloperoxidase and glutathione peroxidase serum levels in arthriticpatients. Int J Clin Pharmacol Res. 2000; 20(3-4): 69-80.
55.
JokićA, SremcevićN, KaragülleZ, PekmezovićT, DavidovićV. Oxidative stress, hemoglobin content, superoxide dismutase and catalase activity influenced by sulphur bathsand mud packs in patients with osteoarthritis. Vojnosanit Pregl. 2010; 67(7): 573-8.
ShaniJ, BarakS, LeviD, RamM, SchachnerER, SchlesingerT, et al. Skin penetration of minerals in psoriatics and guinea-pigs bathing in hypertonic salt solutions. Pharmacol Res Commun. 1985; 17(6): 501-12.
58.
MassicotteF, LajeunesseD, BenderdourM, PelletierJP, HilalG, DuvalN, et al. Can altered production of interleukin-1beta, interleukin-6, transforming growth factor-beta and prostaglandin E(2) by isolated human subchondral osteoblasts identify two subgroups of osteoarthritic patients. Osteoarthritis Cartilage. 2002; 10(6): 491-500.
59.
KonttinenYT, MandelinJ, LiTF, SaloJ, LassusJ, LiljeströmM, et al. Acidic cysteine endoproteinase cathepsin K in the degeneration of the superficial articular hyaline cartilage inosteoarthritis. Arthritis Rheum. 2002; 46(4): 953-60.
60.
NakaseT, KanekoM, TomitaT, MyouiA, ArigaK, SugamotoK, et al. Immunohistochemical detection of cathepsin D, K, and L in the process of endochondral ossification in thehuman. Histochem Cell Biol. 2000; 114(1): 21-7.
61.
Martel-PelletierJ, BoileauC, PelletierJP, RoughleyPJ. Cartilage in normal and osteoarthritis conditions. Best Pract Res Clin Rheumatol. 2008; 22(2): 351-84. doi: 10.1016/j.berh.2008.02.001.
62.
MoldovanF, PelletierJP, HamborJ, CloutierJM, Martel-PelletierJ. Collagenase-3 (matrix metalloprotease 13) is preferentially localized in the deep layer of human arthritic cartilagein situ: In vitro mimicking effect by transforming growth factor beta. Arthritis Rheum. 1997; 40(9): 1653-61.
63.
ChevalierX, ConrozierT. Biological markers for osteoarthritis: An update. Joint Bone Spine. 2005; 72(2): 106-9.
64.
AntoniouJ, SteffenT, NelsonF, WinterbottomN, HollanderAP, PooleRA, et al. The human lumbar intervertebral disc: evidence for changes in the biosynthesis anddenaturation of the extracellular matrix with growth, maturation, ageing, and degeneration. J Clin Invest. 1996; 98(4): 996-1003.
65.
MouritzenU, ChristgauS, LehmannHJ, TankóLB, ChristiansenC. Cartilage turnover assessed with a newly developed assay measuring collagen type IIdegradation products: influence of age, sex, menopause, hormone replacement therapy, and body mass index. Ann Rheum Dis. 2003; 62(4): 332-6.
66.
KongSY, StablerTV, CriscioneLG, ElliottAL, JordanJM, KrausVB. Diurnal variation of serum and urine biomarkers in patients with radiographic knee osteoarthritis. Arthritis Rheum. 2006; 54(8): 2496-504.
SprotH. Associations of CTX-II with biochemical markers of bone turnover raise questions about itstissue origin: Data from CHECK, a cohort study of early osteoarthritis. Ann Rheum Dis. 2013; 72: e20. doi: 10.1136/annrheumdis-2013-203805.
69.
ChristgauS, CloosPAS. Cartilage degradation products as markers for evaluation of patients with rheumatic disease. Clin Appl Immunol Rev. 2004; 4: 277-294.
70.
CozziF, CarraraM, SfrisoP, TodescoS, CimaL. Anti-inflammatory effect of mud-bath applications on adjuvant arthritis in rats. Clin Exp Rheumatol. 2004; 22(6): 763-6.
SukenikS, Abu-ShakraM, FlusserD. Balneotherapy in autoimmune disease. Isr J Med Sci. 1997; 33(4): 258-61.
73.
JezováD, VigasM, TatárP, JurcovicováJ, PalátMRise in plasma beta-endorphin and ACTH in response to hyperthermia in sauna. Horm Metab Res. 1985; 17(12): 693-4.
74.
GalzignaL, Ceschi-BerriniC, MoschinE, TolomioC. Thermal mud-pack as an anti-inflammatory treatment. Biomed Pharmacother. 1998; 52(9): 408-9.
LiuH, ZengC, GaoSG, YangT, LuoW, LiYS, et al. The effect of mud therapy on pain relief in patients with knee osteoarthritis: A meta-analysis of randomized controlled trials. J Int Med Res. 2013; 41(5): 1418-25. doi: 10.1177/0300060513488509.
77.
FrançonA, ForestierR. Spa therapy in rheumatology. Indications based on the clinical guidelines of the French National Authority for health and the European League Against Rheumatism, and the results of 19 randomized clinical trials. Bull Acad Natl Med. 2009; 193(6): 1345-56; discussion 1356-8.
78.
OdabaşıE, TuranM, ErdemH, PayS, GüleçM, KaragülleMZ. The Effect of Mud Pack Treatment in Knee Osteoarthritis. Turk J Rheumato. 2009; 24: 72-6.
79.
EvcikD, KavuncuV, YeterA, YigitI. The efficacy of balneotherapy and mud-pack therapy in patients with knee osteoarthritis. Joint Bone Spine. 2007; 74(1): 60-5.
80.
TefnerIK, GaálR, KoroknaiA, RáthonyiA, GátiT, MondukP, et al. The effect of Neydharting mud-pack therapy on knee osteoarthritis: A randomized, controlled,double-blind follow-up pilot study. Rheumatol Int. 2013; 33(10): 2569-76. doi: 10.1007/s00296-013-2776-2.
